Literature DB >> 15310641

Propofol offers no advantage over isoflurane anesthesia for cerebral protection during cardiopulmonary bypass: a preliminary study of S-100beta protein levels.

Meral Kanbak1, Fatma Saricaoglu, Alev Avci, Turgay Ocal, Zehra Koray, Ulku Aypar.   

Abstract

PURPOSE: Despite advances in anesthesia, cardiopulmonary bypass (CPB) and surgical techniques, cerebral injury remains a major source of morbidity after cardiac surgery. We compared the effects of two different anesthetic techniques, isoflurane vs propofol on neurological outcome by serum S-100beta protein and neuropsychological tests after coronary artery bypass grafting (CABG).
METHODS: Twenty patients undergoing CABG, randomly allocated into two groups, were enrolled in this prospective, controlled, preliminary study. Isoflurane was used in group I and propofol in group P. Neurological examination and a neuropsychologic test battery consisting of the mini mental state examination (MMSET) and the visual aural digit span test (VADST) were obtained preoperatively and on the third and sixth postoperative days. Blood samples for analysis of S-100beta protein were collected before anesthesia (T1), after heparinization (T2), 15 min into CPB (T3), after CPB (T4) and at the 24(th) hr postoperatively (T5).
RESULTS: Postoperative neurological examinations of the patients were normal. VADST performance declined significantly on the third day (P < 0.05) in both groups, and there were no significant differences on VADST and MMSET scores between the two groups. In group P, S-100beta protein levels increased significantly at T3 and T4 compared to preoperative and isoflurane levels (P < 0.05).
CONCLUSIONS: Despite reports about the neuroprotective effects of propofol, S-100beta protein levels were significantly elevated in group P. Although there was no deterioration in neuropsychological outcome, propofol appeared to offer no advantage over isoflurane for cerebral protection during CPB in this preliminary study of 20 patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15310641     DOI: 10.1007/bf03018431

Source DB:  PubMed          Journal:  Can J Anaesth        ISSN: 0832-610X            Impact factor:   5.063


  6 in total

Review 1.  Inhalational anesthetics as neuroprotectants or chemical preconditioning agents in ischemic brain.

Authors:  Hideto Kitano; Jeffrey R Kirsch; Patricia D Hurn; Stephanie J Murphy
Journal:  J Cereb Blood Flow Metab       Date:  2006-10-18       Impact factor: 6.200

2.  Volatile isoflurane sedation in cerebrovascular intensive care patients using AnaConDa(®): effects on cerebral oxygenation, circulation, and pressure.

Authors:  Julian Bösel; Jan C Purrucker; Frank Nowak; Julian Renzland; Petra Schiller; Eva Benveniste Pérez; Sven Poli; Benjamin Brunn; Werner Hacke; Thorsten Steiner
Journal:  Intensive Care Med       Date:  2012-10-25       Impact factor: 17.440

Review 3.  Anaesthetic-related neuroprotection: intravenous or inhalational agents?

Authors:  Daniela Schifilliti; Giovanni Grasso; Alfredo Conti; Vincenzo Fodale
Journal:  CNS Drugs       Date:  2010-11       Impact factor: 5.749

Review 4.  Neuroprotective effects of intravenous anesthetics: a new critical perspective.

Authors:  Federico Bilotta; Elisabetta Stazi; Alexander Zlotnik; Shaun E Gruenbaum; Giovanni Rosa
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

5.  Complex assessment of the incidence and risk factors of delirium in a large cohort of cardiac surgery patients: a single-center 6-year experience.

Authors:  Lukasz J Krzych; Maciej T Wybraniec; Irena Krupka-Matuszczyk; Michał Skrzypek; Anna Bolkowska; Mirosław Wilczyński; Andrzej A Bochenek
Journal:  Biomed Res Int       Date:  2013-12-22       Impact factor: 3.411

Review 6.  Comparison of the cerebroprotective effect of inhalation anaesthesia and total intravenous anaesthesia in patients undergoing cardiac surgery with cardiopulmonary bypass: a systematic review and meta-analysis.

Authors:  Feng Chen; Guangyou Duan; Zhuoxi Wu; Zhiyi Zuo; Hong Li
Journal:  BMJ Open       Date:  2017-10-11       Impact factor: 2.692

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.